Christopher R. Cogle, MD

Where You Are:
Christopher R. Cogle, MD

Office  (352) 273-7493

Education And Training
  • Postdoctoral Fellow, University of Florida, 2003 - Medical Oncology
  • Postdoctoral Fellow, Duke University, 2003 - Bone Marrow and Stem Cell Transplantation
  • Resident, University of Florida, 2000 - Internal Medicine
  • MD, University of Florida, 1997

Dr. Cogle's research focus is on the hemangioblast potential of normal and malignant hematopoietic stem/progenitor cells.  Using unique mouse models of neovaculogenesis he discovered that adult human hematopoietic stem and progenitor cells generate both blood and blood vessels- adult hemangioblast activity.  He has translated this discovery into novel therapies for cariovascular disease.  His lab servces as an NIH Core Lab which assays bone marrow function in subject enrolled in cell therapy trials after myocardial infarction.

In addition, using animals models of cancer neovessel formation, he defined the role of the hematopoietic stem cell contributing to new blood vessels within cancers.  Dr. Cogle is identifying critical pathways in how cancers co-opt the bone marrow for neovessell formation.

Dr. Cogle's lab also studies the co-dependent relationship between leukemia and blood vessels.  Using xenotransplant modles of human leukemia, he tests novel anti-vascular strategies for the treatment of hematologic malignancies like acute myelogenous leukemia and myelodysplastic syndromes.

  • Cogle CR, Bosse RC, Brewer T, Migdady Y, Shirzad R, Kampen KR, Saki N. Acute myeloid leukemia in the vascular niche. Cancer Lett. 2015 May. Pubmedid: 25963886.
  • Kim M, Rahman MM, Cogle CR, McFadden G. Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease. Biochem Bioph Res Co. 2015 Apr. Pubmedid: 25843801.
  • Eldjerou LK, Cogle CR, Rosenau EH, Lu X, Bennett CA, Sugrue MW, Hoyne J, Lambert A, Ashley L, Sazama K, Fields G, Wingard JR, Zubair AC. Vitamin D effect on umbilical cord blood characteristics: a comparison between African Americans and Caucasians. Transfusion. 2015 Apr. Pubmedid: 25903156.
  • Villa NY, Wasserfall CH, Meacham A, Wise E, Chan W, Wingard JR, McFadden G, Cogle CR. Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. Blood. 2015 Apr. Pubmedid: 25904246.
  • Schutt RC, Trachtenberg B, Cooke JP, Traverse JH, Henry TD, Pepine CJ, Willerson JT, Perin EC, Ellis SG, Zhao D, Bhatnagar A, Johnstone BH, Lai D, Resende M, Ebert RF, Wu JC, Sayre SL, Orozco A, Zierold C, Simari RD, Moyé L, Cogle CR, Taylor D. Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial. Circ Res. 2015 Jan;116(1):99-107. Pubmedid: 25406300. Pmcid: PMC4282599.
  • Schmit JM, Turner DJ, Hromas RA, Wingard JR, Brown RA, Li Y, Li MM, Slayton WB, Cogle CR. Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome. Leuk Res Rep. 2015;4(1):24-27. Pubmedid: 25893166. Pmcid: PMC4398854.
  • Cogle CR. Response to letter regarding article, "a detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b and clonogenic capacity as biomarkers for clinical outcomes". Circ Res. 2014 Dec;115(12):e36-e37. Pubmedid: 25477487. Pmcid: PMC4258876.
  • Cogle CR, Wise E, Meacham AM, Zierold C, Traverse JH, Henry TD, Perin EC, Willerson JT, Ellis SG, Carlson MA, Zhao D, Bolli R, Cooke JP, Anwaruddin S, Bhatnagar A, Cabreira-Graca M, Grant MB, Lai D, Moyé L, Ebert RF, Olson RE, Sayre SL, Schulman IH, Scott EW, Simari RD, Pepine CJ, Taylor D. Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes. Circ Res. 2014 Oct;115(10):867-874. Pubmedid: 25136078. Pmcid: PMC4358751.
  • Cogle CR, Goldman DC, Madlambayan GJ, Leon RP, Al Masri A, Clark HA, Asbaghi SA, Tyner JW, Dunlap J, Fan G, Kovacsovics T, Liu Q, Meacham A, Hamlin KL, Hromas RA, Scott EW, Fleming WH. Functional integration of acute myeloid leukemia into the vascular niche. Leukemia. 2014 Oct;28(10):1978-1987. Pubmedid: 24637335. Pmcid: PMC4167983.
  • Kim S, Cogle C, Zingler M, Scott E, Raizada M. Angiotensin II regulates hematopoietic stem cell proliferation, differentiation and engraftment efficacy. Exp Hematol. 2014 Aug;42(8 Suppl):S43. Pubmedid: 25106271.
  • Lopez D, Lin L, Monaghan JR, Cogle CR, Bova FJ, Maden M, Scott EW. Mapping hematopoiesis in a fully regenerative vertebrate: the axolotl. Blood. 2014 Aug;124(8):1232-1241. Pubmedid: 24802774. Pmcid: PMC4141514.
  • Cogle CR. Fishing for myelodysplastic syndromes finds uncaptured cases by state cancer registries: Need for more resources. Cancer. 2014 Jun;120(11):1614-1616. Pubmedid: 24643687.
  • Cogle CR. Radiation alone for solid tumors and the questionable development of therapy-related myelodysplastic syndromes. J Natl Cancer Inst. 2014 Mar;106(3):dju025. Pubmedid: 24577814.
  • Cogle CR, Iannacone MR, Yu D, Cole AL, Imanirad I, Yan L, Mackinnon JA, List AF, Rollison DE. High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment. Leuk Res. 2014 Jan;38(1):71-75. Pubmedid: 24280283.
  • Szady AD, Pepine CJ, Sharma SV, Cogle CR, Perin EC, Ellis SG, Moyé LA. A critical analysis of clinical outcomes reported in stem cell trials for acute myocardial infarction: some thoughts for design of future trials. Curr Atheroscler Rep. 2013 Aug;15(8):341. Pubmedid: 23793731. Pmcid: PMC3800160.
  • Wray J, Williamson EA, Singh SB, Wu Y, Cogle CR, Weinstock DM, Zhang Y, Lee SH, Zhou D, Shao L, Hauer-Jensen M, Pathak R, Klimek V, Nickoloff JA, Hromas R. PARP1 is required for chromosomal translocations. Blood. 2013 May;121(21):4359-4365. Pubmedid: 23568489. Pmcid: PMC3663429.
  • Cogle CR. Overcoming chronic myeloid leukemia stem cell resistance to imatinib by also targeting JAK2. J Natl Cancer Inst. 2013 Mar;105(6):378-379. Pubmedid: 23446756.
  • Craig BM, Rollison DE, List AF, Cogle CR. Underreporting of myeloid malignancies by United States cancer registries. Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):474-481. Pubmedid: 22237987. Pmcid: PMC3662977.
  • Craig BM, Rollison DE, List AF, Cogle CR. Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes. Leuk Res. 2011 Nov;35(11):1453-1456. Pubmedid: 21851978. Pmcid: PMC3191243.
  • Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Forder JR, Byrne BJ, Hatzopoulos AK, Penn MS, Perin EC, Baran KW, Chambers J, Lambert C, Raveendran G, Simon DI, Vaughan DE, Simpson LM, Gee AP, Taylor DA, Cogle CR, Thomas JD, Silva GV, Jorgenson BC, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Smith DX, Baraniuk S, Piller LB, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. Jama. 2011 Nov;306(19):2110-2119. Pubmedid: 22084195. Pmcid: PMC3600981.
  • Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011 Jun;117(26):7121-7125. Pubmedid: 21531980. Pmcid: PMC3143554.
  • Rahman MM, Madlambayan GJ, Cogle CR, McFadden G. Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. Cytokine Growth Factor Rev. 2010 Sep;21(2-3):169-175. Pubmedid: 20211576. Pmcid: PMC2881168.
  • Gee AP, Richman S, Durett A, McKenna D, Traverse J, Henry T, Fisk D, Pepine C, Bloom J, Willerson J, Prater K, Zhao D, Koç JR, Ellis S, Taylor D, Cogle C, Moyé L, Simari R, Skarlatos S. Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience. Cytotherapy. 2010 Sep;12(5):684-691. Pubmedid: 20524773. Pmcid: PMC3600982.
  • Madlambayan GJ, Meacham AM, Hosaka K, Mir S, Jorgensen M, Scott EW, Siemann DW, Cogle CR. Leukemia regression by vascular disruption and antiangiogenic therapy. Blood. 2010 Sep;116(9):1539-1547. Pubmedid: 20472832. Pmcid: PMC2938842.
  • Willerson JT, Perin EC, Ellis SG, Pepine CJ, Henry TD, Zhao DX, Lai D, Penn MS, Byrne BJ, Silva G, Gee A, Traverse JH, Hatzopoulos AK, Forder JR, Martin D, Kronenberg M, Taylor DA, Cogle CR, Baraniuk S, Westbrook L, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyé LA, Simari RD. Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design. Am Heart J. 2010 Aug;160(2):215-223. Pubmedid: 20691824. Pmcid: PMC2921924.
  • Cogle CR, Imanirad I, Wiggins LE, Hsu J, Brown R, Scornik JC, Wingard JR. Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. Clin Adv Hematol Oncol. 2010 Jan;8(1):40-46. Pubmedid: 20351682.
  • Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Simpson LM, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Baraniuk S, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyè LA, Simari RD. LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J. 2010;37(4):412-420. Pubmedid: 20844613. Pmcid: PMC2929864.
  • Madlambayan GJ, Butler JM, Hosaka K, Jorgensen M, Fu D, Guthrie SM, Shenoy AK, Brank A, Russell KJ, Otero J, Siemann DW, Scott EW, Cogle CR. Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger. Blood. 2009 Nov;114(19):4310-4319. Pubmedid: 19717647. Pmcid: PMC2774559.
  • Traverse JH, Henry TD, VaughAn DE, Vaughn DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Piller LB, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moye' LA, Simari RD. Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. Am Heart J. 2009 Sep;158(3):356-363. Pubmedid: 19699857. Pmcid: PMC2784639.
  • Buzzeo MP, Scott EW, Cogle CR. The hunt for cancer-initiating cells: a history stemming from leukemia. Leukemia. 2007 Aug;21(8):1619-1627. Pubmedid: 17541397.
  • Sanders RC, Slayton WB, Cogle CR, Fisher RC, Scott EW. Stem cell research. Paediatr Respir Rev. 2006 Jun;7(2):135-140. Pubmedid: 16765300.
  • Cogle CR, Guthrie SM, Sanders RC, Allen WL, Scott EW, Petersen BE. An overview of stem cell research and regulatory issues. Mayo Clin Proc. 2003 Aug;78(8):993-1003. Pubmedid: 12911047.
  • Cogle CR, Moreb JS, Leather HL, Finiewicz KJ, Khan SA, Reddy VS, Wingard JR. Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma. Am J Hematol. 2003 Jul;73(3):169-175. Pubmedid: 12827653.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions